Most Favored Nation
Resources
Blog Posts
Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the “Most Favored Nation” pricing proposal on patient access in America.
Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access
​
​
Chronic Voices, Critical Choices YouTube Series
To shed some light on concerns about the Most Favored Nation proposal and its impact on people living with chronic conditions, the Partnership to Fight Chronic Disease (PFCD) is hosting short discussions with health and policy experts to address challenges to patient access, discriminatory value metrics like the QALY, and threats to future innovation.
​
PFCD's Vice President of Policy Candace DeMatteis and Global Colon Cancer Association CEO Andrew Spiegel dive into the real-world consequences of the federal government’s proposed “Most Favored Nation” (MFN) drug pricing model for cancer patients. They explore how importing foreign price controls could restrict access to cutting-edge treatments, slow innovation, and jeopardize the U.S. leadership in cancer research.
​
​
​
In this conversation, PFCD’s Ken Thorpe and Caregiver Action Network CEO Marvell Adams examine how “Most Favored Nation” drug pricing could reshape access to medicines for Medicaid beneficiaries. They discuss the potential ripple effects on caregivers, including added burdens from restricted access or disrupted care, and consider the broader equity implications for vulnerable populations. The discussion also explores practical policy alternatives that protect affordability while preserving innovation and reliable access to lifesaving treatments.
Hear what National Organization for Rare Diseases CEO Pam Gavin has to say about the impacts of adopting "Most Favored Nation" and foreign reference pricing on people's access to lifesaving therapies for rare disease.
​​​​​
​​​
Listen to what former Congressman Larry Bucshon, MD thinks as he sheds light on concerns about the proposal and its impact on people living with chronic conditions, particularly related to patient access, discriminatory value metrics like the QALY, and threats to future innovation.
PFCD Statements and Comment Letters
The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D.
The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to President Trump’s most recent efforts to impose “Most Favored Nation” (MFN) drug pricing, which poses considerable risks to patient access, particularly to people living with one or more chronic diseases.
​
​
​
​
​
​
​
The Partnership to Fight Chronic Disease (PFCD) issued the following statement in strong opposition to President Donald Trump’s "Most Favored Nation" (MFN) executive order, which aims to tie prescription drug prices in the U.S. to those in foreign countries
​
The Partnership to Fight Chronic Disease (PFCD) today called on Congressional leaders and the Trump Administration to ensure that treatment access for people living with chronic diseases in Medicaid remains a priority across new policies that aim to make America healthy now and in the future.​​